Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 12Unknown 2Terminated 2Recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 66Genitourinary 35Other hematologic neoplasm 22Thoracic 2Myeloid 2Gynecologic 2Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Other solid neoplasm 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Burkitt Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

venetoclax 33fludarabine 32Cyclophosphamide 31Azacitidine 29Specimen Handling 27Biopsy 20Cytarabine 19fludarabine phosphate 15Whole-Body Irradiation 15Stem Cell Transplantation 15Decitabine 15ruxolitinib 14Tacrolimus 14Melphalan 14Busulfan 14Mycophenolic Acid 13Injections 11asciminib 10decitabine and cedazuridine drug combination 9Thiotepa 8Methotrexate 8Hematopoietic Stem Cell Transplantation 8X-Rays 7Granulocyte Colony-Stimulating Factor 7Magnetic Resonance Spectroscopy 6Idarubicin 6Filgrastim 6Cyclosporine 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6tagraxofusp 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Prednisone × Myeloid × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT03595917 2025-11-04

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Dana-Farber Cancer Institute

Phase 1 Recruiting
40 enrolled
LymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡